Independent global B2B platform
Expert in API & CDMO market
Direct contact between you and supplier

Find, compare & contact
Tiludronate API Manufacturers & Suppliers

Real trade data

Filters

Reset current filters

Type
Production region
Qualifications
Country of origin
Contact suppliers

Located in:

France

Producer

Produced in:

Unknown

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Tiludronate API 89987-06-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Tiludronate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Tiludronate 
Synonyms:
Acide tiludronique , Acido tiludronico , Acidum tiludronicum , Tiludronate , Tiludronic acid  
Cas Number:
89987-06-4 
DrugBank number:
DB01133 
Unique Ingredient Identifier:
6PNS59HP4Y

About Tiludronate

More information about this product: Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to etidronic acid and clodronic acid These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone. Tiludronic acid was granted FDA approval on 7 March 1997.

More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.

Tiludronate is a type of Means for diseases of the bone and muscular system


The pharmaceutical API subcategory known as "Means for diseases of the bone and muscular system" refers to a specialized class of active pharmaceutical ingredients (APIs) designed to target and treat various disorders related to the skeletal and muscular systems. These APIs play a crucial role in the development of medications that alleviate symptoms and improve the quality of life for individuals affected by bone and muscular conditions.

One common group of APIs in this subcategory includes bisphosphonates, which are widely used for the treatment of osteoporosis. These compounds inhibit bone resorption, thereby increasing bone density and reducing the risk of fractures. Bisphosphonates act by targeting specific enzymes involved in bone breakdown, preventing excessive bone loss.

Another significant class of APIs for bone and muscular diseases are muscle relaxants. These compounds help alleviate muscle spasms and stiffness associated with conditions such as muscle strains, sprains, and certain neurological disorders. Muscle relaxants work by interfering with the signals sent between the brain and the muscles, inducing relaxation and reducing pain.

Additionally, APIs like calcitonin analogs are utilized for the management of conditions such as Paget's disease and osteoporosis. Calcitonin analogs function by inhibiting osteoclast activity, reducing bone resorption, and promoting bone formation.

In summary, the subcategory of "Means for diseases of the bone and muscular system" encompasses APIs that target bone metabolism, muscle relaxation, and bone remodeling processes. These pharmaceutical ingredients play a vital role in the development of medications aimed at improving the well-being and mobility of individuals suffering from bone and muscular disorders.


Tiludronate (Means for diseases of the bone and muscular system), classified under Metabolic Bone Disease Agents


Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.



Tiludronate manufacturers | traders | suppliers

We have 1 companies offering Tiludronate produced in 1 different countries.

Get in contact with the supplier of your choice:

  • Sanofi from France, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.